|
Ramos-Muntada M, Trincado JL, Blanco J, Bueno C, Rodriguez-Cortez VC, Bataller A, Lopez-Millan B, Schwab C, Ortega M, Velasco P, Blanco ML, Nomdedeu J, Ramirez-Orellana M, Minguela A, Fuster JL, Cuatrecasas E, Camos M, Ballerini P, Escherich G, Boer J, DenBoer M, Hernandez-Rivas JM, Calasanz MJ, Cazzaniga G, Harrison CJ, Menendez P, Molina O. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia. Mol Oncol. 2022 Aug;16(16):2899-2919. doi: 10.1002/1878-0261.13276. Epub 2022 Jul 19. PubMed PMID: 35726693; PubMed Central PMCID: PMC9394234.
AÑO: 2022; IF: 6.6
|
35726693
|
Ferrandez-Pujante A, Perez-Silva A, Serna-Munoz C, Fuster-Soler JL, Galera-Minarro AM, Cabello I, Ortiz-Ruiz AJ. Prevention and Treatment of Oral Complications in Hematologic Childhood Cancer Patients: An Update. Children (Basel). 2022 Apr 15;9(4):566. doi: 10.3390/children9040566. PubMed PMID: 35455610; PubMed Central PMCID: PMC9029683.
AÑO: 2022; IF: 2.835
|
|
Martinez-Sanchez MV, Fuster JL, Campillo JA, Galera AM, Bermudez-Cortes M, Llinares ME, Ramos-Elbal E, Pascual-Gazquez JF, Fita AM, Martinez-Banaclocha H, Galian JA, Gimeno L, Muro M, Minguela A. Expression of NK Cell Receptor Ligands on Leukemic Cells Is Associated with the Outcome of Childhood Acute Leukemia. Cancers (Basel). 2021 May 11;13(10):2294. doi: 10.3390/cancers13102294. PubMed PMID: 34064810; PubMed Central PMCID: PMC8151902.
AÑO: 2021; IF: 6.575
|
|
Gimeno L, Gonzalez-Lozano I, Soto-Ramirez MF, Martinez-Sanchez MV, Lopez-Cubillana P, Fuster JL, Martinez-Garcia J, Martinez-Escribano J, Campillo JA, Pons-Fuster E, Ferri B, Lopez-Abad A, Muro M, Minguela A. CD8+ T lymphocytes are sensitive to NKG2A/HLA-E licensing interaction: role in the survival of cancer patients. Oncoimmunology. 2021 Oct 14;10(1):1986943. doi: 10.1080/2162402X.2021.1986943. eCollection 2021. PubMed PMID: 34676148; PubMed Central PMCID: PMC8525952.
AÑO: 2021; IF: 7.723
|
|
Munoz Builes M, Vela Cuenca M, Fuster Soler JL, Astigarraga I, Pascual Martinez A, Vagace Valero JM, Tong HY, Valentin Quiroga J, Fernandez Casanova L, Escudero Lopez A, Sisinni L, Blanquer M, Mirones Aguilar I, Gonzalez Martinez B, Borobia AM, Perez-Martinez A. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia. BMJ Open. 2020 Jan 8;10(1):e029642. doi: 10.1136/bmjopen-2019-029642. PubMed PMID: 31919123; PubMed Central PMCID: PMC6955478.
AÑO: 2020; IF: 2.692
|